Expert Interview
Discussing the current standard of care for celiac and new therapies in development such as TAK 101; an immune modifying nanoparticle designed to induce gluten-specific tolerance currently in development by Takeda Pharm
Ticker(s): TAKInstitution: Private Practice at Westmed medical group
- Board-certified gastroenterologist and internist.
- Also board-certified in obesity medicine.
- Special interest in weight loss management as well as anti-reflux medicine.
- Published peer-reviewed articles on various academic topics related to gastroenterology.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
